Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Blood (2020) 136 (Supplement 1): 21–22.

DOI: https://doi.org/10.1182/blood-2020-137221

Published: 2020

Journal Articles

Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee

Blood (2020) 136 (Supplement 1): 27–29.

DOI: https://doi.org/10.1182/blood-2020-137589

Published: 2020

Journal Articles

Acute Myeloid Leukemia (AML) Treated with Azacitidine: Survival Outcomes for Patients Who Complete More Than Six Cycles Are Similar to High-Risk Myelodysplastic Syndrome/Low Blast Count AML

Jill Fulcher, MD PhD FRCPath, Zahra Abdrabalamir Alshammasi, MD, Nathan Cantor, BSc, Christopher Bredeson, MDFRCPC,MSc, Grace Christou, MD, Dawn Maze, MDFRCPC,MSc, Mitchell Sabloff, MSc,MDFRCPC, Jill Fulcher, MD PhD MRCPI FRCPath(UK)

Blood (2019) 134 (Supplement_1): 5156.

DOI: https://doi.org/10.1182/blood-2019-122122

Published: 2019

Journal Articles

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

Mohamad Sobh, PharmD, Lothar B. Huebsch, MD, Mitchell Sabloff, MSc,MDFRCPC, Jill Fulcher, MDPhDMRCPI FRCPath(UK), Sultan Altouri, MDFRCPC, Michael Kennah, MD, Elizabeth Drouin, MD, David S. Allan, MD FRCPC, MSc, Harold Atkins, MD, Grace Christou, MD, Pierre Villeneuve, MD PhD, Alexandre P.Blanchard, PhD, Kelsey Maclellan, Ranjeeta Mallick, PhD MSc, BSc, Nicole B. Laferriere, MD PhD, Sathish Gopalakrishnan, MD, Sita D. Bhella, MD, Natasha Kekre, MDFRCPC, Christopher Bredeson, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 3263.

DOI: https://doi.org/10.1182/blood-2019-122436

Published: 2019

Journal Articles

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Blood (2019) 134 (Supplement_1): 3323.

DOI: https://doi.org/10.1182/blood-2019-125865

Published: 2019

Journal Articles

Provincial Disparities in Access to Allogeneic Transplant in Canada

Kristjan Paulson, MD, Oliver Bucher, Geoffrey Cuvelier, MD, Andrew Daly, MD, Alina S. Gerrie, MD MPH, David Sanford, MD, David Szwajcer, MD FRCP(C), Matthew Seftel, MRCP, MD MPH, FRCPC, Irwin Walker, MBBS, Natasha Kekre, MD FRCPC, Tony H Truong, MD FRCPC, Donna Wall, MD CCPE, Kirk R. Schultz, MD, Stephen Couban, MDBSc, Christopher Bredeson, MD FRCPC, MSc

Blood (2018) 132 (Supplement 1): 4742.

DOI: https://doi.org/10.1182/blood-2018-99-113849

Published: 2018

Journal Articles

The Impact of Marital Status on Hematopoietic Stem Cell Transplant (HCT) Recipient Outcomes: A Surrogate for Consistent Caregiver. a CIBMTR Registry Study

Jason Tay, MD, Ruta Brazauskas, PhD, Naya He, Sara Beattie, Christopher Bredeson, MD FRCPC, MSc, Jignesh Dalal, MD, Shahrukh K. Hashmi, MD MPH, Theresa E. Hahn, PhD, Nandita Khera, MD, William A. Wood, MD MPH, Wael Saber, MD MS

Blood (2018) 132 (Supplement 1): 4788.

DOI: https://doi.org/10.1182/blood-2018-99-117027

Published: 2018

Journal Articles

Complications and Toxicities Associated with Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: Single Center Experience

Shona Philip, BSc, MSc, MD, Christopher Bredeson, MD FRCPC, MSc, David S. Allan, MD FRCPC, MSc, Sultan Altouri, MD FRCPC, Lothar B. Huebsch, MD, Harold Atkins, MD, Natasha Kekre, MD FRCPC

Blood (2018) 132 (Supplement 1): 4624.

DOI: https://doi.org/10.1182/blood-2018-99-119797

Published: 2018

Journal Articles

Autologous Stem Cell Transplant for Myasthenia Gravis: A Single-Centre Experience

Adam Bryant, MD, Elizabeth Pringle, MD, Christopher Bredeson, MD MSc, FRCPC, David S. Allan, MD MSc, Grizel Anstee, Isabelle Bence-Bruckler, Linda Hamelin, Harry Spencer Hopkins, Lothar B. Huebsch, MD, Mitchell Sabloff, MDM, Dawn C. Sheppard, MDFRCPC,MSc, Jason Tay, MD MSc, Harold Atkins, MD

Blood (2014) 124 (21): 3996.

DOI: https://doi.org/10.1182/blood.V124.21.3996.3996

Published: 2014

Journal Articles

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI

Blood (2013) 122 (24): 3863–3870.

DOI: https://doi.org/10.1182/blood-2013-07-514448

Published: 2013

Journal Articles

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation

Clinical Trials & Observations

Christopher Bredeson, Jennifer LeRademacher, Kazunobu Kato, John F. DiPersio, Edward Agura, Steven M. Devine, Frederick R. Appelbaum, Marcie R. Tomblyn, Ginna G. Laport, Xiaochun Zhu, Philip L. McCarthy, Vincent T. Ho, Kenneth R. Cooke, Elizabeth Armstrong, Angela Smith, J. Douglas Rizzo, Jeanne M. Burkart, Marcelo C. Pasquini

Blood (2013) 122 (24): 3871–3878.

DOI: https://doi.org/10.1182/blood-2013-08-519009

Published: 2013

Includes: Supplemental data

Journal Articles

Utility of Pre-Induction Cardiac Function Testing in Patients with Newly Diagnosed AML

Adam Bryant, MD, Dawn Sheppard, MD, MSc, FRCPC, Christopher Bredeson, MD, MSc, FRCPC, Mitchell Sabloff, MDCM, FRCPC, MSc

Blood (2012) 120 (21): 2068.

DOI: https://doi.org/10.1182/blood.V120.21.2068.2068

Published: 2012

Journal Articles

Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT)

Parameswaran Hari, MBBS, MD, MRCP, Todd E. Defor, MS, David H. Vesole, MD, PhD, Christopher Bredeson, MD, MSc, FRCPC, Linda J Burns, MD

Blood (2012) 120 (21): 1965.

DOI: https://doi.org/10.1182/blood.V120.21.1965.1965

Published: 2012

Journal Articles

Risk factors for acute GVHD and survival after hematopoietic cell transplantation

Clinical Trials & Observations

Blood (2012) 119 (1): 296–307.

DOI: https://doi.org/10.1182/blood-2011-06-364265

Published: 2012

Journal Articles

Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantation for Hematologic Malignancies,

Dawn Sheppard, MD, MSc, FRCPC, Jason Tay, MD, MSc, FRCPC, Christopher Bredeson, MD, MSc, FRCPC, David S. Allan, MD, FRCPC

Blood (2011) 118 (21): 4046.

DOI: https://doi.org/10.1182/blood.V118.21.4046.4046

Published: 2011

Journal Articles

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, Leanthe Braunert, MD, Ginna G. Laport, MD, Thomas Chauncey, MD, Christopher Bredeson, Richard T Maziarz, MD, Michael A. Pulsipher, MD, Edward Agura, MD, Michael T. Maris, MD, Lars Vindelov, MD, Firoozeh Sahebi, M.D., Peter McSweeney, Benedetto Bruno, MD, Amelia Langston, MD, Rainer F. Storb, MD, David G. Maloney

Blood (2010) 116 (21): 2364.

DOI: https://doi.org/10.1182/blood.V116.21.2364.2364

Published: 2010

Journal Articles

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Blood (2010) 116 (21): 3450.

DOI: https://doi.org/10.1182/blood.V116.21.3450.3450

Published: 2010

Journal Articles

Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors – An Analysis of the CIBMTR

Blood (2010) 116 (21): 897.

DOI: https://doi.org/10.1182/blood.V116.21.897.897

Published: 2010

Journal Articles

Patterns of Serum Free Light Chain (FLC) Recovery After Reduced Intensity Conditioning (RIC) Allogeneic Transplant for Multiple Myeloma (MM) Predict Long Term Outcomes

Veerpal Singh, MD, Mazie, Froedtert, Willms, &, Sue, Froedtert, Cancer, Fellow, Frank Frank Cornell, MD, Sirisha Paruchuri, MD, Marc Sala, MD, Ayman Saad, MD, Christopher Bredeson, Jeanne Palmer, MD, Parameswaran Hari, MD

Blood (2010) 116 (21): 1301.

DOI: https://doi.org/10.1182/blood.V116.21.1301.1301

Published: 2010

Journal Articles

High Prevalence of Dapsone-Induced Oxidant Hemolysis in North American Stem Cell Transplant Recipients without Glucose-6-Phosphate-Dehydrogenase Deficiency.

Horatiu Olteanu, MD, PhD, Alexandra Harrington, MD, Ben George, MD, Christopher Bredeson, MD, Parameswaran N. Hari, MD, MS, Steven Kroft, MD

Blood (2009) 114 (22): 3314.

DOI: https://doi.org/10.1182/blood.V114.22.3314.3314

Published: 2009

NARROW

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Acute Myeloid Leukemia (AML) Treated with Azacitidine: Survival Outcomes for Patients Who Complete More Than Six Cycles Are Similar to High-Risk Myelodysplastic Syndrome/Low Blast Count AML

Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Provincial Disparities in Access to Allogeneic Transplant in Canada

The Impact of Marital Status on Hematopoietic Stem Cell Transplant (HCT) Recipient Outcomes: A Surrogate for Consistent Caregiver. a CIBMTR Registry Study

Complications and Toxicities Associated with Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: Single Center Experience

Autologous Stem Cell Transplant for Myasthenia Gravis: A Single-Centre Experience

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation

Utility of Pre-Induction Cardiac Function Testing in Patients with Newly Diagnosed AML

Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT)

Risk factors for acute GVHD and survival after hematopoietic cell transplantation

Systematic Review of Randomized Controlled Trials of Hematopoietic Stem Cell Mobilization Strategies for Autologous Transplantation for Hematologic Malignancies,

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors – An Analysis of the CIBMTR

Patterns of Serum Free Light Chain (FLC) Recovery After Reduced Intensity Conditioning (RIC) Allogeneic Transplant for Multiple Myeloma (MM) Predict Long Term Outcomes

High Prevalence of Dapsone-Induced Oxidant Hemolysis in North American Stem Cell Transplant Recipients without Glucose-6-Phosphate-Dehydrogenase Deficiency.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only